Analyst firms · Morgan Stanley · DNLI

Morgan Stanley DNLI price target and rating history

Denali Therapeutics Inc. (DNLI) · Health Care

Morgan Stanley rates Denali Therapeutics Inc. (DNLI) Overweight with a $33 price target, as of its latest action on Mar 7, 2025. It has published 3 rating actions on DNLI since August 2021, including 0 upgrades and 0 downgrades. Across 3 firms with a DNLI price target in the last 12 months, the median target is $35.

Current rating
Overweight
Price target
$33
Median target, all firms
$35
Actions on DNLI
3

Morgan Stanley price target on DNLI

$99$66$3320222023202420252026
Morgan Stanley price target on DNLI, each point a stated target, August 2021 to March 2025.

Every Morgan Stanley rating on DNLI

How other firms rate DNLI

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Wells FargoOverweight$35Nov 13, 2026
H.C. WainwrightBuy$42Mar 26, 2026
Wolfe ResearchPeer PerformFeb 24, 2026
UBSBuy$25Jan 7, 2026

Questions about Morgan Stanley and DNLI

What is Morgan Stanley's price target for DNLI?
Morgan Stanley's latest stated price target for Denali Therapeutics Inc. (DNLI) is $33, from its action on Mar 7, 2025.
What is Morgan Stanley's rating on DNLI?
Morgan Stanley rates DNLI Overweight, a bullish rating, as of Mar 7, 2025.
When did Morgan Stanley last change its view on DNLI?
On Mar 7, 2025, Morgan Stanley resumes coverage at Overweight, price target $41 to $33.
How does Morgan Stanley's DNLI target compare with other analysts?
Across 3 firms with a DNLI price target in the last 12 months, the median target is $35.

More DNLI rating histories

All Morgan Stanley ratingsDNLI news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.